Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy
- Authors: Knyazev O.V.1,2,3, Khomeriki S.G.1, Kagramanova A.V.1, Lishchinskaya A.A.1, Smirnova O.A.1, Noskova K.K.1, Parfenov A.I.1
-
Affiliations:
- Loginov Moscow Clinical Scientific Center
- Ryzhykh National Medical Research Center of Coloproctology
- Research Institute of Health Organization and Medical Management
- Issue: Vol 93, No 12 (2021)
- Pages: 1435-1442
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/96434
- DOI: https://doi.org/10.26442/00403660.2021.12.201212
- ID: 96434
Cite item
Full Text
Abstract
Aim. To conduct comparative analysis of histological remission in patients with moderate and severe ulcerative colitis (UC), receiving biological therapy vedolizumab, mesenchymal stem cell (MSC) treatment and combined stem cells and vedolizumab therapy.
Materials and methods. We studied biopsies of 75 patients with total or left-sided moderate and severe ulcerative colitis, divided into groups depending on treatment. The first group of UC patients (n=29) received stem cell therapy 2 mln per kg; the second group of UC patients (n=27) received vedolizumab and the third group (n=19) – MSC and vedolizumab. The efficacy of treatment was assessed by C reactive protein (CRP), Mayo score (MS), fecal calprotectin (FC) and Geboes score (GS).
Results. We determined medium correlation between basic FC and MS before treatment (r=0.6605, p<0.05). After 12 weeks of treatment in the first group of UC patients (n=29) CRP was 7.8±2.1 mg/l, FC 409.3±44.85 µg/g, medium GS 1.2±0.1 points. After 12 weeks of treatment in the second group of UC patients (n=27) CRP was 8.4±1.4 mg/l, FC 435.5±47.3 µg/g, medium GS 1.35±0.15 points. After 12 weeks of treatment in the third group of UC patients (n=19) CRP was 6.4±1.1 mg/l, FC 290.6±17.5 µg/g, medium GS 0.9±0.1 points. We proved strong direct relationship between FC and GS after 12 weeks of treatment in UC patients, receiving MSC (r=0.8392, p<0.05). The statistically significant majority of patients, achieved histological remission, have less than 5-year duration of disease.
Conclusion. Our study showed that clinical and endoscopic remission in UC patients does not always correlate with histological remission. Combined anti-cytokine and stem cells therapy contributes to achieve deep remission and decrease mucosa inflammation rather than single MSC or vedolizumab treatment. Deep remission could be achieved by earlier start of biological therapy. FC could be a predictor and marker of mucosa healing and histological remission
Full Text
##article.viewOnOriginalSite##About the authors
Oleg V. Knyazev
Loginov Moscow Clinical Scientific Center; Ryzhykh National Medical Research Center of Coloproctology; Research Institute of Health Organization and Medical Management
Email: asfold@mail.ru
ORCID iD: 0000-0001-7250-0977
д-р мед. наук, зав. отд-нием воспалительных заболеваний кишечника, проф. научно-образовательного отд., вед. специалист организационно-методического отд. по колопроктологии, вед. науч. сотр.
Russian Federation, Moscow; Moscow; MoscowSergey G. Khomeriki
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0003-4308-8009
д-р мед. наук, проф., рук. научно-исследовательского отд. патоморфологии
Russian Federation, MoscowAnna V. Kagramanova
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0002-3818-6205
канд. мед. наук, ст. науч. сотр. отд-ния воспалительных заболеваний кишечника
Russian Federation, MoscowAlbina A. Lishchinskaya
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0001-7891-2702
канд. мед. наук, ст. науч. сотр. отд-ния воспалительных заболеваний кишечника
Russian Federation, MoscowOlga A. Smirnova
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0002-0088-4075
мл. науч. сотр. лаб. нутрициологии
Russian Federation, MoscowKarina K. Noskova
Loginov Moscow Clinical Scientific Center
Email: asfold@mail.ru
ORCID iD: 0000-0001-5734-0995
канд. мед. наук, зав. клинико-диагностической лаб.
Russian Federation, MoscowAsfold I. Parfenov
Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: asfold@mail.ru
ORCID iD: 0000-0002-9782-4860
д-р мед. наук, проф., рук. отд. патологии кишечника
Russian Federation, MoscowReferences
- Хатьков И.Е., Парфенов А.И., Князев О.В., и др. Воспалительные заболевания кишечника в практике терапевта и хирурга. М.: Вита-ПРЕСС, 2017 [Khat’kov IE, Parfenov AI, Knyazev OV, et al. Vospalitel’nye zabolevaniia kishechnika v praktike terapevta i khirurga. Moscow: Vita-PRESS, 2017 (in Russian)].
- Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324-38. doi: 10.1038/ajg.2015.233
- Turner D, Ricciuto A, Lewis A, et al.; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi: 10.1053/j.gastro.2020.12.031
- Ungaro R, Colombel JF, Lissoos T, et al. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114(6):874-83. doi: 10.14309/ajg.0000000000000183
- Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9(6):483-9.e3. doi: 10.1016/j.cgh.2010.12.028
- Zenlea T, Yee EU, Rosenberg L, et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. Am J Gastroenterol. 2016;111:685-90. doi: 10.1038/ajg.2016.50
- Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-14. doi: 10.1136/gutjnl-2015-309598
- Тертычный А.С., Ахриева Х.М., Маев И.В., и др. Проблемы диагностики гистологической ремиссии у больных с воспалительными заболеваниями кишечника. Архив патологии. 2017;79(3):3-9 [Tertychnyi AS, Akhrieva KhM, Maev IV, et al. Problemy diagnostiki gistologicheskoi remissii u bol’nykh s vospalitel’nymi zabolevaniiami kishechnika. Arkhiv patologii. 2017;79(3):3-9 (in Russian)]. doi: 10.17116/patol20177933-9
- Narang V, Kaur R, Garg B, et al. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intest Res. 2018;16:55-61. doi: 10.5217/ir.2018.16.1.55
- Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut. 2017;66:50-8. doi: 10.1136/gutjnl-2015-310393
- Bopanna S, Roy M, Das P, et al. Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer. Intest Res. 2016;14:264-9. doi: 10.5217/ir.2016.14.3.264
- Colman RJ, Rubin DT. Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. Intest Res. 2016;14:202-10. doi: 10.5217/ir.2016.14.3.202
- Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J. 1956;1:1315-8. doi: 10.1136/bmj.1.4979.1315
- Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404-9. doi: 10.1136/gut.47.3.404
- Löwenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease. Gastroenterology. 2019;157(4):997-1006.e6. doi: 10.1053/j.gastro.2019.05.067
- Knyazev O, Kagramanova A, Kulakov D, et al. Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis. J Crohns Colitis. 2019;13(Suppl. 1):S350. doi: 10.1093/ecco-jcc/jjy222.600
- Knyazev O, Kagramanova A, Lishchinskaya A, et al. Combined therapy with mesenchymal stromal cells and vedolizumab contributes to deep remission in ulcerative colitis. United European Gastroenterol J. 2019;7(8S):628. doi: 10.1177/2050640619854663/journals.sagepub.com/home/ueg
- Князев О.В., Парфенов А.И. Клеточные технологии и биологическая терапия хронических воспалительных заболеваний кишечника. М.: Вита-ПРЕСС, 2020; с. 310 [Knyazev OV, Parfenov AI. Kletochnye tekhnologii i biologicheskaia terapiia khronicheskikh vospalitel’nykh zabolevanii kishechnika. Moscow: Vita-PRESS, 2020; p. 310 (in Russian)].
- Malvão LDR, Madi K, Esberard BC, et al. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore). 2021;100(3):e24058. doi: 10.1097/MD.0000000000024058
- Щукина О.Б., Кондрашина Э.А., Харитидис А.М., и др. Оценка гистологических показателей у больных с клинической ремиссией язвенного колита. Acta Biomedica Scientifica. 2014;(6):39-43 [Shchukina OB, Kondrashina EA, Kharitidis AM, et al. Evaluation of histological parameters in patients with clinical remission of ulcerative colitis. Acta Biomedica Scientifica. 2014;(6):39-43 (in Russian)].
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625-9. doi: 10.1056/NEJM198712243172603
- Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi: 10.1016/j.stem.2013.09.006
- Terai S, Tsuchiya A. Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis. J Gastroenterol. 2017;52(2):129-40. doi: 10.1007/s00535-016-1258-1
- Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-201. doi: 10.1053/j.gastro.2011.06.054
- Patel A, Panchal H, Dubinsky MC. Fecal calprotectin levels predict histological healing in ulcerative colitis. Inflam Bowel Dis. 2017;23:1600-4. doi: 10.1097/MIB.0000000000001157
- Zittan E, Kelly OB, Kirsch R, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease. Inflam Bowel Dis. 2016;22:623-30. doi: 10.1097/MIB.0000000000000652
- Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22. doi: 10.1097/00005176-200107000-00003